OPKO Health (NASDAQ:OPK) Upgraded at StockNews.com

OPKO Health (NASDAQ:OPK) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Wednesday.

Other equities analysts have also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research report on Monday, August 7th. Piper Sandler raised their target price on OPKO Health from $4.00 to $5.00 in a research report on Monday, August 7th.

OPKO Health Price Performance

OPK stock opened at $1.39 on Wednesday. OPKO Health has a 12-month low of $1.00 and a 12-month high of $2.24. The stock has a 50-day moving average price of $1.45 and a two-hundred day moving average price of $1.65. The company has a current ratio of 1.78, a quick ratio of 1.44 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.07 billion, a PE ratio of -5.15 and a beta of 1.84.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). OPKO Health had a negative net margin of 23.94% and a negative return on equity of 13.63%. The business had revenue of $178.60 million for the quarter, compared to analyst estimates of $174.78 million. During the same quarter last year, the business earned ($0.11) EPS. OPKO Health’s revenue for the quarter was down .6% compared to the same quarter last year. As a group, research analysts predict that OPKO Health will post -0.24 EPS for the current year.

Insider Activity at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 100,000 shares of the stock in a transaction dated Thursday, August 17th. The shares were bought at an average cost of $1.76 per share, for a total transaction of $176,000.00. Following the purchase, the chief executive officer now owns 200,956,694 shares in the company, valued at approximately $353,683,781.44. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock in a transaction on Thursday, August 17th. The shares were purchased at an average price of $1.76 per share, with a total value of $176,000.00. Following the acquisition, the chief executive officer now owns 200,956,694 shares in the company, valued at $353,683,781.44. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Richard C. Pfenniger, Jr. acquired 25,000 shares of OPKO Health stock in a transaction on Monday, November 13th. The shares were purchased at an average cost of $1.30 per share, for a total transaction of $32,500.00. Following the acquisition, the director now owns 300,000 shares in the company, valued at approximately $390,000. The disclosure for this purchase can be found here. Insiders have bought 735,000 shares of company stock worth $988,500 over the last three months. Company insiders own 42.62% of the company’s stock.

Institutional Trading of OPKO Health

Several institutional investors and hedge funds have recently made changes to their positions in the business. Trellus Management Company LLC bought a new stake in shares of OPKO Health in the 2nd quarter valued at $161,000. Oak Thistle LLC bought a new position in OPKO Health during the 2nd quarter worth about $36,000. Bailard Inc. bought a new position in OPKO Health during the 2nd quarter worth about $62,000. Wilbanks Smith & Thomas Asset Management LLC increased its holdings in OPKO Health by 21.1% during the 1st quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 131,380 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 22,930 shares in the last quarter. Finally, Raymond James & Associates increased its holdings in OPKO Health by 19.5% during the 2nd quarter. Raymond James & Associates now owns 49,346 shares of the biotechnology company’s stock worth $107,000 after purchasing an additional 8,051 shares in the last quarter. Institutional investors own 22.03% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.